# A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event

Study · id `cardio:ct-nct07000123` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07000123](<https://clinicaltrials.gov/study/NCT07000123>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07000123

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 3103 participants.

## Technical summary

Registry record NCT07000123. Randomized; triple masking; primary purpose treatment. Start 2025-05-28 (actual); primary completion 2027-01-11 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 3103 participants (enrolled count; ClinicalTrials.gov record NCT07000123, source copy `cardio:ctgov-nct07000123-2026-08-11`, retrieved 2026-10-31)
- Started: 2025-05-28 (actual) (ClinicalTrials.gov record NCT07000123, source copy `cardio:ctgov-nct07000123-2026-08-11`, retrieved 2026-10-31)
- Primary completion: 2027-01-11 (anticipated) (ClinicalTrials.gov record NCT07000123, source copy `cardio:ctgov-nct07000123-2026-08-11`, retrieved 2026-10-31)
- Completion: 2027-01-11 (anticipated) (ClinicalTrials.gov record NCT07000123, source copy `cardio:ctgov-nct07000123-2026-08-11`, retrieved 2026-10-31)
- Countries: United States; Argentina; Australia; Brazil; Bulgaria; Canada; Chile; Czechia; Germany; Hungary; India; Japan; Malaysia; Poland; Slovakia; South Korea; Spain; Taiwan; Türkiye; Ukraine; United Kingdom; Vietnam (ClinicalTrials.gov record NCT07000123, source copy `cardio:ctgov-nct07000123-2026-08-11`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07000123-2026-08-11`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event
- Acronym: AZURE-LDL
- Condition: Cardiovascular Disease
- Intervention (Drug): AZD0780
- Intervention (Drug): Placebo
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: f3e40100301be87fa69bc53ee7ed5c4965162a0fa52326634c614fbc09b91f05
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
